Article and Video CATEGORIES
As part of our program on lung cancer highlights, Dr. Joel Neal covered the LUX-Lung 3 trial, a global study that randomized patients with advanced NSCLC and an EGFR mutation to either afatinib, an "irreversible pan-HER inhibitor" that could potentially be an advance over the current EGFR inhibitors we have available now, or standard chemotherapy with cisplatin/Alimta (pemetrexed). It provided some interesting results, though the question is whether the performance of afatinib exceeded what we might expect from Tarceva (erlotinib) or Iressa (gefitinib), except in terms of side effects, which were more severe and more common with afatinib. Still, it was a positive trial that I expect will lead to an FDA approval and the commercial availability of afatinib for this clinical population.
Here's Dr. Neal's coverage of the trial, in both video and audio podcast form, as well as the associated transcript and figures for the podcast.
Dr. Neal ASCO 2012 LC Highlights LUX-Lung 3 Audio Podcast
Dr. Neal ASCO 2012 LC Highlights LUX-Lung 3 Figs
Dr. Neal ASCO LC Highlights 2012 LUX-Lung 3 Transcript
In short order we'll have Dr. Neal's summary of the interesting trial of the MEK inhibitor selumetinib for KRAS mutation-positive patients available, too; in the meantime, what do you think of these results? Would you be inclined to favor afatinib now if you had an EGFR mutation, or would you favor Iressa or Tarceva instead? How much does your answer depend on the survival results for the afatinib?
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Revtoby, Welcome to Grace. I'm sorry you and your wife are worried about cancer but we couldn't say whether or not your wife's leison is cancer no matter how much...
Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...
Hello and welcome to Grace. I'm sorry you're going through this worry. It is normal to watch a small very slow-growing solid nodule with once-a-year CT scans. Anything less than a...
Thanks you very much. So in summary the course of action taken suggested by lung specalist (re scan in 12 months) seems appropriate? And a PET at this stage is probably...
I can't say what is appropriate for you that's only something your professionals with all your information can do. However, when someone has a solid nodule less than a cm that...